Research comparison
Semaglutide vs Tirzepatide
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and obesity (Wegovy). By mimicking the incretin hormone GLP-1, it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central hypothalamic pathways. Landmark trials demonstrate up to 15–17% body weight reduction and significant cardiovascular mortality benefit.
Research Status
FDA Approved
Half-Life
~1 week (allows once-weekly dosing)
Molecular Formula
—
Molecular Weight
—
CAS Number
910463-68-2
Research Categories
GLP-1 & Metabolic Hormones, Fat Loss & Metabolic, Cardiovascular
Routes of Administration
Tirzepatide is the first dual GIP/GLP-1 receptor agonist, approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). By co-activating both incretin receptors, it achieves superior glycemic control and weight reduction compared to GLP-1 monotherapy — SURMOUNT trials showed up to 22.5% body weight reduction. It represents a new class of metabolic peptide therapeutics with broad cardiovascular and metabolic benefits.
Research Status
FDA Approved
Half-Life
~5 days (once-weekly dosing)
Molecular Formula
—
Molecular Weight
—
CAS Number
2023788-19-2
Research Categories
GLP-1 & Metabolic Hormones, Fat Loss & Metabolic
Routes of Administration
Full mechanism comparison
Mechanism of action, pharmacokinetics, and research findings comparison available on the Researcher plan.
Unlock full comparison →Related comparisons